HPV Vaccine May Cut Preterm Birth Risk, Study Finds

The HPV vaccine may protect more than you think. A large Swedish study published in The BMJ this week found that people who received the HPV vaccine before pregnancy were less likely to give birth prematurely, adding a surprising new benefit to a shot most people associate only with cancer prevention. The protective link was strongest in those vaccinated before their seventeenth birthday.

Researchers at the Karolinska Institutet in Sweden drew on national health registers covering more than six hundred twenty thousand first-time singleton births among mothers aged sixteen to thirty-five, recorded between 2006 and 2023. About one in seven of those mothers, more than ninety-two thousand women, had received the quadrivalent HPV vaccine before becoming pregnant. That formulation targets four common types of the virus, including types sixteen and eighteen, which together cause around seventy percent of cervical cancers, according to The Pharmacist's summary of the research.

What the Numbers Show on the HPV Vaccine

Compared with unvaccinated mothers, those who had received the HPV vaccine were around five percent less likely to give birth before thirty-seven weeks, and around fifteen percent less likely to deliver very prematurely, between weeks twenty-eight and thirty-one of a forty-week pregnancy. The vaccinated group was also seven percent less likely to experience a rupture of the amniotic membrane before labor, and eight percent less likely to have a baby that was much smaller than expected for its stage of pregnancy, as reported by CIDRAP. That early-delivery finding matters because babies born very prematurely face higher risks of lasting health problems and disabilities.

The timing of the shot mattered. Among women vaccinated before age seventeen, the risk of premature delivery was ten percent lower than among unvaccinated mothers, the risk of premature membrane rupture was fourteen percent lower, and the risk of a baby being small for its gestational age was nine percent lower. Researchers say the pattern likely reflects the fact that younger recipients had not yet been exposed to the virus, which spreads through sexual contact. As doctoral researcher Zhongsong Zhang put it, the associations were stronger among women who had been vaccinated before the age of seventeen, according to News-Medical.

What the Study Can't Prove

This is where the caveats come in, and they matter. The study was observational, which means it found associations rather than proving the HPV vaccine directly prevents pregnancy complications. The authors accounted for factors including smoking, body mass index, maternal health conditions, assisted reproduction, country of birth, income, and education, but they acknowledge that unmeasured factors could still have influenced the results, and that information on spontaneous abortions was incomplete.

Still, the finding fits a pattern scientists have been watching. Previous research has linked HPV infection itself, as well as treatments for cervical cell changes caused by the virus, to a higher risk of pregnancy complications including preterm birth. One plausible explanation is that preventing the infection avoids the downstream cervical procedures that can weaken the cervix, though the researchers note the biological pathways need more investigation. The sheer scale of the data, drawn from high-quality national registers with long follow-up, makes the signal hard to dismiss. The researchers also stress that the results do not change how the shot is used today. It remains a cancer prevention tool first, and any pregnancy benefit would be an added reason to get vaccinated on schedule rather than a reason to seek it out later in life for that purpose alone. The findings underscore why timing matters: protection appears strongest when the series is finished well before any pregnancy is on the horizon.

For readers, the takeaway is practical. The HPV vaccine is already recommended in early adolescence in many countries, including school-based programs in the United Kingdom that have offered it to twelve- and thirteen-year-olds since 2012, as the Nursing Times noted. If you skipped the shot as a teen or are still deciding, this study adds another data point to the conversation to have with your doctor. It is worth remembering that the vaccine's primary job remains cancer prevention, and that this possible pregnancy benefit is a bonus finding, not the reason to get it.

And if health research is your thing, the health section has more on how early-life factors shape later outcomes, including the surprising link between the brain's repair system and tumors.